9,10-dimethyl-1,2-benzanthracene has been researched along with canagliflozin in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| El-Sherbiny, M; Ibrahim, TM; Sabaa, M; Said, E; Salem, HA; Sharawy, MH | 1 |
1 other study(ies) available for 9,10-dimethyl-1,2-benzanthracene and canagliflozin
| Article | Year |
|---|---|
Canagliflozin interrupts mTOR-mediated inflammatory signaling and attenuates DMBA-induced mammary cell carcinoma in rats.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Canagliflozin; Carcinoma; Caspase 1; Female; Inflammation Mediators; Ki-67 Antigen; Mammary Neoplasms, Experimental; NLR Family, Pyrin Domain-Containing 3 Protein; Rats; Rats, Sprague-Dawley; Signal Transduction; TOR Serine-Threonine Kinases | 2022 |